2 results
Approved WMOPending
To compare ACM at Day 42 following treatment with olorofim versus treatment with AmBisome® followed by SOC in the intent-to-treat (ITT) population of patients with IFD caused by proven IA at any site or probable lower respiratory tract disease (LRTD…
Approved WMOPending
Primary objective: To measure AF burden at population level.Secondary objective: Associate the AF burden with risk profiles in the general population.